ANALYSIS OF DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) MICROENVIRONMENT IN REGARD TO DRUG RESISTANCE PATTERNS
DOI:
https://doi.org/10.48047/HM.10.2.2024.1536-1543Keywords:
Diffuse Large B-Cell Lymphoma (DLBCL), Hematological Malignancy, Drug Resistance, Tumor Microenvironment, Chemotherapy.Abstract
Lymphomas are one of the most common hematological malignancies, characterized into Hodgkin’s Lymphoma (HL) and Non-Hodgkin’s Lymphoma (NHL). Diffuse Large B-cell Lymphoma (DLBCL) is the most common type of NHL, often seen in patients diagnosed with genetic immunological deficiencies. It accounts for nearly one third of all the new cases of NHL. Tumor Microenvironment (TME) has helped to explain the heterogeneous nature of DLBCL and has a surfeit of immune cells, blood vessels, extracellular matrix (ECM) and stroma cells, influencing the tumor behavior and subsequently drug resistance. This study aimed to analyze selective drug resistant marker panel; MDR1 and EMT (E- Cadherin, Vimentin and SNAI1) to predict their role in tumor microenvironment of DLBCL. Using blood samples of 28 patients, total RNA was extracted by TRIzol method and cDNA synthesis was performed. DNA primers were designed using bioinformatics tools and optimized using conventional PCR. Further, quantification of drug resistant markers was carried out using RT-qPCR. The results showed an insignificant expression of MDR 1 in DLBCL patients suggesting sensitivity to the drug being administered. In DLBCL, the expression of E-Cadherin was higher than Vimentin and SNAI-1 suggesting there was no progression towards epithelial to mesenchymal transition (EMT). On the contrary, nodal marginal zone lymphoma (NMZL) showed a significantly higher expression of Vimentin and SNAI-1 indicating progression of EMT. The expression of these biomarkers in association to drug resistance, can help us gain a better understanding of the tumor microenvironment. Contributing to improved prognosis and therapeutic methods in aggressive tumors.
Downloads
References
Sung H, Ferlay J, Siegel RL et al., Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-249.
Mugnaini EN, Ghosh N. Lymphoma. Prim Care. 2016 Dec;43(4):661-675.
Thomas AG, Vaidhyanath R, Kirke R et al., Extranodal lymphoma from head to toe: part 1, the head and spine. AJR Am J Roentgenol. 2011 Aug;197(2):350-6.
Xu-Monette ZY, Zhang H, Zhu Fet al., A refined cell-of-origin classifier with targeted NGS and artificial intelligence shows robust predictive value in DLBCL. Blood Adv. 2020 Jul 28;4(14):3391-3404.
Martelli M, Ferreri AJ, Agostinelli C et al., Diffuse large B-cell lymphoma. Crit Rev Oncol Hematol. 2013 Aug;87(2):146-71.
Chigrinova E, Rinaldi A, Kwee I et al., Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome. Blood. 2013 Oct 10;122(15):2673-82.
Jamroziak K, Tadmor T, Robak T et al., Richter syndrome in chronic lymphocytic leukemia: updates on biology, clinical features and therapy. Leuk Lymphoma. 2015 Jul;56(7):1949-58.
Parikh SA, Shanafelt TD. Risk factors for Richter syndrome in chronic lymphocytic leukemia. Curr Hematol Malig Rep. 2014 Sep;9(3):294-9
Erin N, Grahovac J, Brozovic A et al., Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance. Drug Resist Updat. 2020 Dec;53:100715
Andreadis C, Gimotty PA, Wahl P et al., Members of the glutathione and ABC-transporter families are associated with clinical outcome in patients with diffuse large B-cell lymphoma. Blood. 2007 Apr 15;109(8):3409-16.
Goldman O, Valdes VJ, Ezhkova E et al., The mesenchymal transcription factor SNAI-1 instructs human liver specification. Stem Cell Res. 2016 Jul;17(1):62-8.
Saentaweesuk W, Araki N, Vaeteewoottacharn K et al., Activation of Vimentin Is Critical to Promote a Metastatic Potential of Cholangiocarcinoma Cells. Oncol Res. 2018 May 7;26(4):605-616.
Andl CD, Rustgi AK. No one-way street: cross-talk between e-cadherin and receptor tyrosine kinase (RTK) signaling: a mechanism to regulate RTK activity. Cancer Biol Ther. 2005 Jan;4(1):28-31.
Na TY, Schecterson L, Mendonsa AM et al., The functional activity of E-cadherin controls tumor cell metastasis at multiple steps. Proc Natl Acad Sci U S A. 2020 Mar 17;117(11):5931-5937.
Qi J, Li T, Bian H et al., SNAI1 promotes the development of HCC through the enhancement of proliferation and inhibition of apoptosis. FEBS Open Bio. 2016 Mar 10;6(4):326-37.
Furuya S, Endo K, Takahashi A et al., Snail suppresses cellular senescence and promotes fibroblast-led cancer cell invasion. FEBS Open Bio. 2017 Sep 11;7(10):1586-1597.
Han L, Luo H, Huang W et al., Modulation of the EMT/MET Process by E-Cadherin in Airway Epithelia Stress Injury. Biomolecules. 2021 Apr 30;11(5):669.
Liang C, Zhao J, Lu J et al., Development and Characterization of MDR1 (Mdr1a/b) CRISPR/Cas9 Knockout Rat Model. Drug Metab Dispos. 2019 Feb;47(2):71-79.
Brinkmann U. Functional polymorphisms of the human multidrug resistance (MDR1) gene: correlation with P glycoprotein expression and activity in vivo. Novartis Found Symp. 2002;243:207-10; discussion 210-2, 231-5.
Cai QC, Liao H, Lin SX et al., High expression of tumor-infiltrating macrophages correlates with poor prognosis in patients with diffuse large B-cell lymphoma. Med Oncol. 2012 Dec;29(4):2317-22.
Zhang J, Yan Y, Yang Y et al., High Infiltration of Tumor-Associated Macrophages Influences Poor Prognosis in Human Gastric Cancer Patients, Associates With the Phenomenon of EMT. Medicine (Baltimore). 2016 Feb;95(6):e2636.
Jordaan G, Liao W, Sharma S. E-cadherin gene re-expression in chronic lymphocytic leukemia cells by HDAC inhibitors. BMC Cancer. 2013 Feb 25;13:88.
Maxwell SA, Cherry EM, Bayless KJ. Akt, 14-3-3ζ, and vimentin mediate a drug-resistant invasive phenotype in diffuse large B-cell lymphoma. Leuk Lymphoma. 2011 May;52(5):849-64.
Julien S, Puig I, Caretti E et al., Activation of NF-kappaB by Akt upregulates Snail expression and induces epithelium mesenchyme transition. Oncogene. 2007 Nov 22;26(53):7445-56.
Yagi K, Yamamoto K, Umeda S et al., Expression of multidrug resistance 1 gene in B-cell lymphomas: association with follicular dendritic cells. Histopathology. 2013 Feb;62(3):414-20.
Lemma S, Karihtala P, Haapasaari KM et al., Biological roles and prognostic values of the epithelial-mesenchymal transition-mediating transcription factors Twist, ZEB1 and Slug in diffuse large B-cell lymphoma. Histopathology. 2013 Jan;62(2):326-33.
Zheng H, Shen M, Zha YL et al., PKD1 phosphorylation-dependent degradation of SNAIL by SCF-FBXO11 regulates epithelial-mesenchymal transition and metastasis. Cancer Cell. 2014 Sep 8;26(3):358-373.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Author
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
